11 reports

Brodalumab is a novel human monoclonal antibody that binds to the interleukin-## (IL-##) receptor and inhibits inflammatory signaling by blocking the binding of several types of IL-## to the receptor.

  • Eyewear
  • Northern Europe
  • United Kingdom
  • Abbott Medical Optics, Inc.
  • Alcon, Inc.

The company' s product cataract emulsifier find applications in glaucoma therapeutic treatment by reducing pressure buildup in the eye using specific monoclonal antibodies.

  • Clinical Trial
  • Eye Disease
  • Eyewear
  • Ophthalmology
  • Bausch & Lomb Incorporated

Regulatory submissions and filings AMG ## (erenumab) became the first anti-CGRP monoclonal antibody to be submitted to both FDA and EMA for migraine prevention.

  • Clinical Trial
  • Eye Disease
  • Eyewear
  • Ophthalmology
  • Novartis AG

Regulatory submissions and filings AMG ## (erenumab) became the first anti-CGRP monoclonal antibody to be submitted to both FDA and EMA for migraine prevention.

  • Eyewear
  • Medical Device
  • United States
  • Company
  • Valeant Pharmaceuticals International, Inc.

The Phase III ARISE study of the fully human monoclonal antibody AMG ## (erenumab) in episodic migraine prevention met its primary endpoint of a statistically significant reduction in the number of monthly migraine days versus placebo.

  • Clinical Trial
  • Eye Disease
  • Eyewear
  • Ophthalmology
  • Valeant Pharmaceuticals International, Inc.

One unit refers to one toric foldable intraocular lens.

  • Eyewear
  • Canada
  • North America
  • Company
  • Valeant Pharmaceuticals International, Inc.

One unit refers to one microkeratome.

  • Eyewear
  • Ophthalmic Solution
  • North America
  • Forecast
  • Valeant Pharmaceuticals International, Inc.

The entire contract includes several pharmaceuticals based of monoclonal antibodies produced in Russia by BIOCAD.

  • Eyewear
  • Healthcare
  • North America
  • United States
  • Alcon, Inc.

One unit refers to one toric foldable intraocular lens.

  • Eyewear
  • North America
  • United States
  • Forecast
  • Alcon, Inc.

Investment in research and development increased $## million, or ##%, to $## million in the first quarter of 2016, primarily due to the development programs related to the Company' s dermatology product portfolio, including IDP- ##, as well as brodalumab, an IL-## receptor monoclonal

  • Eyewear
  • Ophtalmic Surgery Device
  • Canada
  • North America
  • Valeant Pharmaceuticals International, Inc.

The Phase III ARISE study of the fully human monoclonal antibody AMG ## (erenumab) in episodic migraine prevention met its primary endpoint of a statistically significant reduction in the number of monthly migraine days versus placebo.

  • Eyewear
  • Medical Device
  • United States
  • Company
  • Valeant Pharmaceuticals International, Inc.